Relates to capping cost sharing for antiviral COVID-19 therapeutics
Summary
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Bill status
passed
3 of 5 stages cleared
Introduction
Jan 2024
Committee Review
Jun 2024
Senate Passage
Jun 2024
Assembly Passage
Governor
Introduced Jan 23, 2024
Last action Jun 5, 2024
Floor votes · Senate Jun 5, 2024
How they voted
59–0
Passed · 3 other
Total votes 62
Jun 5, 2024
D
Democratic41
95% Yea
R
Republican21
95% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
10
Key actions
5
Committee
3
Amendments
4
Jun 5, 2024
Committee
REFERRED TO INSURANCE
lower
Jun 5, 2024
Upper · Passed
PASSED SENATE
upper
May 28, 2024
Committee
COMMITTEE DISCHARGED AND COMMITTED TO RULES
upper
May 7, 2024
Upper · Passed
PRINT NUMBER 8367B
upper
May 7, 2024
Upper · Passed
AMEND AND RECOMMIT TO INSURANCE
upper
Mar 7, 2024
Upper · Passed
PRINT NUMBER 8367A
upper
Mar 7, 2024
Upper · Passed
AMEND (T) AND RECOMMIT TO INSURANCE
upper
Jan 23, 2024
Committee
REFERRED TO INSURANCE
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brad Hoylman-Sigal
DDemocratic/Working Families
Ask Maddy
·
AI policy assistant
Ask Maddy about S 8367
Scope: NY
Hi! I can help you understand S 8367. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline